Combined treatment with two drugs targeting different points in the same growth-factor pathway delayed the development of treatment resistance in patients with BRAF-positive metastatic malignant melanoma .
ShareFriday, November 2, 2012
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment